Publication | Open Access

T cells armed with anti-CD3 × anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro

Cancer ImmunosurveillanceT CellsImmune RegulationTumor ImmunityImmunologyT Cell ImmunityImmunotherapeuticsCell TransplantationCellular Immune ResponseImmunotherapyMedicineRadiation OncologyAntibody Biology